original ) (raw )Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients
Mohammad Hamid Hamdard
Scientific Reports
View PDFchevron_right
Genetic Determinants of CYP2C19 Gene *2 and *3 Loss of Function Alleles and Response to Anti Platelet Therapy (Clopidogrel) and Cardiovascular Events. (A Study in Kashmir, North India)
Faheem Shehjar
Biology and medicine, 2015
View PDFchevron_right
Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy
S. Braun
Journal of Thrombosis and Haemostasis, 2010
View PDFchevron_right
Genetic determinants of platelet response to clopidogrel
Marek Koziński
Journal of Thrombosis and Thrombolysis, 2011
View PDFchevron_right
Association of Polymorphisms in CYP2C19 with the Efficacy of Clopidogrel Therapy in South Indian Patients Undergoing Percutaneous Coronary Intervention
Vijay Kumar Kutala
Journal of cardiovascular disease research, 2017
View PDFchevron_right
The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases
Marta Karaźniewicz-Łada
The Journal of Clinical Pharmacology, 2014
View PDFchevron_right
Relationship between clopidogrel-related polymorphisms and variable platelet reactivity at 1 year: A cohort study from Han Chinese
yan lai
Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2016
View PDFchevron_right
Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day
In-Suk Kim
JACC: Cardiovascular Interventions, 2010
View PDFchevron_right
CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention
George Kassimis , A. Athanassiadou
Thrombosis Research, 2012
View PDFchevron_right
Genetic Polymorphisms of CYP2C19 and Resistance to Clopidogrel Therapy among Iranian Patients Suffering from Ischemic Heart Disease
Behzad Poopak
Research in Molecular Medicine
View PDFchevron_right
High on-clopidogrel platelet reactivity: Genotyping Can help to optimize antiplatelet treatment
Pascale GAUSSEM
Thrombosis Research, 2011
View PDFchevron_right
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients
Gian Franco Gensini
Pharmacogenetics and Genomics, 2007
View PDFchevron_right
Coexisting Polymorphisms of P2Y12 and CYP2C19 Genes as a Risk Factor for Persistent Platelet Activation With Clopidogrel
Zenon Huczek
Circulation Journal, 2008
View PDFchevron_right
Effect of cytochrome P450 3A5 polymorphism on platelet reactivity after treatment with clopidogrel in patients scheduled for percutaneous coronary intervention
Ahmed Abd Elsalam
The Egyptian Heart Journal, 2011
View PDFchevron_right
The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients
Arwa Amin
Thrombosis research, 2017
View PDFchevron_right
The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel
Evangelos Oikonomou
International Journal of Cardiology, 2013
View PDFchevron_right
The role of CYP2C19 gene polymorphisms on antiplatelet activity of clopidogrel among Arabs: systematic review and meta-analysis
Abdullah Alkattan
2022
View PDFchevron_right
CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors
Apichaya Puangpetch
Pharmacogenomics and Personalized Medicine, 2013
View PDFchevron_right
Impact of CYP2C1 9 polymorphisms on antiplatelet efficacy of clopidogrel in patient s after myocardial infarcti on
Michał Kasprzak , Jacek Kubica , Marek Koziński
View PDFchevron_right
Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome
Corinne Frere
The American Journal of Cardiology, 2008
View PDFchevron_right
Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects
Philippe Moerloose
Journal of Thrombosis and Haemostasis, 2007
View PDFchevron_right
Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting
Jurrien Ten Berg
Heart, 2011
View PDFchevron_right
The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome
Corinne Frere
Journal of Thrombosis and Haemostasis, 2009
View PDFchevron_right
Non-Carriers of Reduced-Function CYP2C19 Alleles are Most Susceptible to Impairment of the Anti-Platelet Effect of Clopidogrel by Proton-Pump Inhibitors: A Pilot Study
Jyh-ming Juang
Acta Cardiologica Sinica, 2016
View PDFchevron_right
The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study
Cansu Ozbayer
Basic & Clinical Pharmacology & Toxicology, 2017
View PDFchevron_right
Correlation Between the CYP2C19 Phenotype Status and the Results of Three Different Platelet Function Tests in Cardiovascular Disease Patients Receiving Antiplatelet Therapy: An Emphasis on Newly Introduced Platelet Function Analyzer-200 P2Y Test
Moo Kim
Annals of laboratory medicine, 2016
View PDFchevron_right
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
Pascale Gaussem
Blood, 2006
View PDFchevron_right
Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients
J. Lorenzi , Marcelo R Pinto , Julio F Marchini
View PDFchevron_right